Arcoma Ab Stock Net Income
| ARCOMA Stock | SEK 7.24 0.08 1.09% |
As of the 4th of February, Arcoma AB shows the mean deviation of 1.69, and Risk Adjusted Performance of (0.07). Arcoma AB technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Arcoma AB's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Arcoma AB's valuation are provided below:Arcoma AB does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Arcoma |
Arcoma AB 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arcoma AB's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arcoma AB.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Arcoma AB on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Arcoma AB or generate 0.0% return on investment in Arcoma AB over 90 days. Arcoma AB is related to or competes with Scibase AB, Biosergen, Iconovo, Luxbright, Neola Medical, Nanologica, and Biovica International. Arcoma AB develops, produces, and provides radiology solutions worldwide More
Arcoma AB Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arcoma AB's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arcoma AB upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 9.91 | |||
| Value At Risk | (3.77) | |||
| Potential Upside | 2.87 |
Arcoma AB Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcoma AB's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arcoma AB's standard deviation. In reality, there are many statistical measures that can use Arcoma AB historical prices to predict the future Arcoma AB's volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.37) | |||
| Treynor Ratio | 2.29 |
Arcoma AB February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 2.3 | |||
| Mean Deviation | 1.69 | |||
| Coefficient Of Variation | (927.37) | |||
| Standard Deviation | 2.14 | |||
| Variance | 4.58 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.24) | |||
| Total Risk Alpha | (0.37) | |||
| Treynor Ratio | 2.29 | |||
| Maximum Drawdown | 9.91 | |||
| Value At Risk | (3.77) | |||
| Potential Upside | 2.87 | |||
| Skewness | 0.1214 | |||
| Kurtosis | (0.09) |
Arcoma AB Backtested Returns
Arcoma AB secures Sharpe Ratio (or Efficiency) of -0.0175, which signifies that the company had a -0.0175 % return per unit of standard deviation over the last 3 months. Arcoma AB exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Arcoma AB's mean deviation of 1.69, and Risk Adjusted Performance of (0.07) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.11, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Arcoma AB are expected to decrease at a much lower rate. During the bear market, Arcoma AB is likely to outperform the market. At this point, Arcoma AB has a negative expected return of -0.0358%. Please make sure to confirm Arcoma AB's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Arcoma AB performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.09 |
Very weak reverse predictability
Arcoma AB has very weak reverse predictability. Overlapping area represents the amount of predictability between Arcoma AB time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arcoma AB price movement. The serial correlation of -0.09 indicates that less than 9.0% of current Arcoma AB price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.09 | |
| Spearman Rank Test | 0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Arcoma AB reported net income of (7.47 Million). This is 102.19% lower than that of the Healthcare sector and 103.14% lower than that of the Medical Devices industry. The net income for all Sweden stocks is 101.31% higher than that of the company.
Arcoma Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcoma AB's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcoma AB could also be used in its relative valuation, which is a method of valuing Arcoma AB by comparing valuation metrics of similar companies.Arcoma AB is currently under evaluation in net income category among its peers.
Arcoma Fundamentals
| Return On Equity | 0.0423 | |||
| Return On Asset | 0.0218 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 112.49 M | |||
| Shares Outstanding | 13.05 M | |||
| Shares Owned By Insiders | 46.73 % | |||
| Shares Owned By Institutions | 25.01 % | |||
| Price To Earning | 70.28 X | |||
| Price To Book | 2.26 X | |||
| Price To Sales | 0.97 X | |||
| Revenue | 117.13 M | |||
| Gross Profit | 55.29 M | |||
| EBITDA | (2.03 M) | |||
| Net Income | (7.47 M) | |||
| Cash And Equivalents | 811 K | |||
| Cash Per Share | 0.06 X | |||
| Total Debt | 1.81 M | |||
| Debt To Equity | 0.43 % | |||
| Current Ratio | 1.46 X | |||
| Book Value Per Share | 3.48 X | |||
| Cash Flow From Operations | (1.93 M) | |||
| Earnings Per Share | (0.81) X | |||
| Target Price | 12.0 | |||
| Number Of Employees | 24 | |||
| Beta | 1.08 | |||
| Market Capitalization | 146.18 M | |||
| Total Asset | 79.27 M | |||
| Retained Earnings | (6 M) | |||
| Working Capital | 15 M | |||
| Current Asset | 47 M | |||
| Current Liabilities | 32 M | |||
| Z Score | 49.0 | |||
| Net Asset | 79.27 M |
About Arcoma AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcoma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcoma AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcoma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Arcoma Stock
Arcoma AB financial ratios help investors to determine whether Arcoma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arcoma with respect to the benefits of owning Arcoma AB security.